Boulding Mark Elliott sold $133K of PTCT
Boulding Mark Elliott (EXEC. VP AND CLO) sold 2,073 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $64.06 ($64.03–$64.16, $0.13M total) across 2 trades over 2026-10-05 to 2026-10-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size but may influence short‑term trading sentiment for PTCT.
Market read
A small insider sell by a senior officer, likely to generate limited but measurable downside pressure.
What to watch
Potential upcoming clinical data could offset any negative sentiment from the insider sell.
Background
Form 4 filings provide the first public disclosure of insider transactions, offering insight into insider sentiment.
Ticker impact
SEC Form 4 disclosed executive Mark Elliott sold 2,073 shares of PTC Therapeutics for $132,791 via a 10b5‑1 plan.
likely modest downward pressure as market prices in the insider sell
The sale is small ($133K) but executed by a senior officer; such transactions often lead to short‑term sell‑side bias.
Market effects
minimal impact on biotech sector
none
none
Counterpoint
The sale could be routine portfolio rebalancing, not a bearish signal.
Key entities
- ExecutiveMark Elliott
Executive Vice President and Chief Legal Officer of PTC Therapeutics
